Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Pharmacogenetic Aspect of Intravitreal Ranibizumab Treatment in Neovascular Age-Related Macular Degeneration: A Five-Year Follow-Up.

Ocular immunology and inflammation - 1 Jan 2018

Sengul Elvan Alper, Artunay Ozgur, Rasier Rifat, Kockar Alev, Afacan Ceyda, Hancer Veysel Sabri, Yuzbasioglu Erdal

Abstract excerpt

PURPOSE: This study aims to evaluate the role of complement factor H (CFH) in response to intravitreal ranibizumab (IVR) treatment, which is administered to patients with neovascular age-related macular degeneration (nAMD). METHODS: In this retrospective study, 90 nAMD patients' 90 eyes were evaluated. IVR was injected once a month for three consecutive months, and then, patients were followed up for five years...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Angiogenesis Inhibitors
Share to Complement Factor H

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Follow-Up Studies

Share to Intravitreal Injections

Share to Pharmacogenetics

Share to Time Factors

Share to Visual Acuity

Share to Wet Macular Degeneration

Source

Identifiers

PMID: 28471284
DOI: 10.1080/09273948.2017.1311925

Genes

CFH

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Pharmacogenetic Aspect of Intravitreal Ranibizumab Treatment in Neovascular Age-Related Macular Degeneration: A Five-Year Follow-Up.PMID 28471284Read ↗

The effect of CFH polymorphisms on the response to the treatment of age-related macular degeneration (AMD) with intravitreal ranibizumab.Semantic proximity Read ↗

Analysis of the association between CFH Y402H polymorphism and response to intravitreal ranibizumab in patients with neovascular age-related macular degeneration (nAMD).Semantic proximity Read ↗

The Role of Complement Factor H in Age-related Macular Degeneration: A ReviewSemantic proximity Read ↗

Pharmacogenetics of antiangiogenic and antineovascular therapies of age-related macular degeneration.Semantic proximity Read ↗

Pharmacogenetics of complement factor H (Y402H) and treatment of exudative age-related macular degeneration with ranibizumab.Semantic proximity Read ↗

Complement Inhibitors in Age-Related Macular Degeneration: A Potential Therapeutic Option.Semantic proximity Read ↗

Association of the Complement Factor H Y402H Polymorphism and Response to Anti-Vascular Endothelial Growth Factor Treatment in Age-Related Macular Degeneration: An Updated Meta-Analysis.Semantic proximity Read ↗

Genetic association with response to intravitreal ranibizumab for neovascular age-related macular degeneration in the Han Chinese population.Semantic proximity Read ↗

Age-Related Maculopathy Susceptibility 2 and Complement Factor H Polymorphism and Intraocular Complement Activation in Neovascular Age-Related Macular DegenerationSemantic proximity Read ↗

Complement proteins and complement regulatory proteins are associated with age-related macular degeneration stage and treatment responseSemantic proximity Read ↗

Pharmacogenetic association with early response to intravitreal ranibizumab for age-related macular degeneration in a Korean population.Semantic proximity Read ↗

Pharmacogenetic Effect of Complement Factor H Gene Polymorphism in Response to the Initial Intravitreal Injection of Bevacizumab for Wet Age-Related Macular Degeneration.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.